阿斯利康AstraZeneca plc (AZN) 2010年年度报告「LSE」.pdf

1、 How does health connect us all?AstraZeneca Annual Report and Form 20-F Information 2010$33.3bnSales unchanged at$33,269 million($32,804 million in 2009)$6.71Core EPS for the full year increased by 5%to$6.71($6.32 in 2009)$2.1bnNet share repurchases totalled$2,110 million($nil in 2009)$13.6bnCore op

2、erating profit unchanged at$13,603 million($13,621 million in 2009)Important information for readers of this Annual Report and Form 20-F InformationCautionary statement regarding forward-looking statementsThe purpose of this Annual Report is to provide information to the members of the Company.The C

3、ompany and its Directors,employees,agents and advisors do not accept or assume responsibility to any other person to whom this Annual Report is shown or into whose hands it may come and any such responsibility or liability is expressly disclaimed.In order,among other things,to utilise the safe harbo

4、ur provisions of the US Private Securities Litigation Reform Act of 1995 and the UK Companies Act 2006,we are providing the following cautionary statement:This Annual Report contains certain forward-looking statements with respect to the operations,performance and financial condition of the Group.Fo

5、rward-looking statements are statements relating to the future which are based on information available at the time such statements are made,including information relating to risks and uncertainties.Although we believe that the forward-looking statements in this Annual Report are based on reasonable

6、 assumptions,the matters discussed in the forward-looking statements may be influenced by factors that could cause actual outcomes and results to be materially different from those expressed or implied by these statements.The forward-looking statements reflect knowledge and information available at